Ghent University Academic Bibliography

Your filters: cql: author="Bartenhagen, Christoph" or (type any "bookEditor issueEditor" and editor="Bartenhagen, Ch...

Add to list
- Journal Article
- A1
- open access
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Carolina de Carvalho Nunes, Lisa Depestel (UGent) , Liselot Mus (UGent) , Kaylee M. Keller, Louis Delhaye (UGent) , Amber Louwagie (UGent) , Muhammad Rishfi (UGent) , Alex Whale, Neesha Kara, Simon R. Andrews, et al.

(2022) SCIENCE ADVANCES. 8(28).
Add to list
Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy

Jingwei Chen, Christopher Nelson, Matthew Wong, Andrew E. Tee, Pei Y. Liu, Ting La, Jamie I. Fletcher, Alvin Kamili, Chelsea Mayoh, Christoph Bartenhagen, et al.

(2021) CLINICAL CANCER RESEARCH. 27(5). p.1438-1451
Add to list
- Journal Article
- A1
- open access
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

Liselot Mus (UGent) , Irina Lambertz (UGent) , Shana Claeys (UGent) , Candy Kumps (UGent) , Wouter Van Loocke (UGent) , Christophe Van Neste (UGent) , Ganesh Umapathy, Marica Vaapil, Christoph Bartenhagen, Genevieve Laureys (UGent) , et al.

(2020) SCIENTIFIC REPORTS. 10.
Add to list
A mechanistic classification of clinical phenotypes in neuroblastoma.

Sandra Ackermann, Maria Cartolano, Barbara Hero, Anne Welte, Yvonne Kahlert, Andrea Roderwieser, Christoph Bartenhagen, Esther Walter, Judith Gecht, Laura Kerschke, et al.

(2018) SCIENCE. 362(6419). p.1165-1170

Academic Bibliography

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

A mechanistic classification of clinical phenotypes in neuroblastoma.

Contents

Support

Contact